Literature DB >> 22023894

Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?

Andrew J Laster1, S Bobo Tanner.   

Abstract

Although a variety of medications are effective for the treatment of postmenopausal osteoporosis, there is concern that long-term use may incur side effects. Consequently, some have proposed discontinuing or temporarily suspending treatment after a defined period of time. As the benefits of fracture risk reduction may recede during this "drug holiday", the clinician may be faced with deciding when to resume therapy (and with which agent) while avoiding the possible cumulative risk of side effects. This article summarizes data regarding length of treatment and the effects of cessation of treatment on bone density, bone turnover markers, and fracture risk.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023894     DOI: 10.1016/j.rdc.2011.07.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  1 in total

1.  Characterisation of Bone Beneficial Components from Australian Wallaby Bone.

Authors:  Weiguo Lao; Xingliang Jin; Yi Tan; Linda Xiao; Matthew P Padula; David P Bishop; Brian Reedy; Madeleine Ong; Mohammad A Kamal; Xianqin Qu
Journal:  Medicines (Basel)       Date:  2016-08-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.